Abramson Cancer Center, University of Pennsylvania
Welcome,         Profile    Billing    Logout  
 30 Trials 
49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DeMichele, Angela
PALLAS, NCT02513394 / 2014-005181-30: PALbociclib CoLlaborative Adjuvant Study

Checkmark Presentation of data from PALLAS trial for ER+/HER2- breast cancer at ASCO 2022
Oct 2022 - Oct 2022: Presentation of data from PALLAS trial for ER+/HER2- breast cancer at ASCO 2022
Hourglass Jan 2021 - Jun 2021 : For early-stage breast cancer (PALLAS study)
Checkmark From PALLAS trial for HR+/HER2- breast cancer at ESMO 2020
Sep 2020 - Sep 2020: From PALLAS trial for HR+/HER2- breast cancer at ESMO 2020
More
Active, not recruiting
3
5796
Europe, Canada, Japan, US, RoW
Palbociclib, Standard Adjuvant Endocrine Therapy
Alliance Foundation Trials, LLC., Austrian Breast & Colorectal Cancer Study Group, NSABP Foundation Inc, PrECOG, LLC., Breast International Group, Pfizer
Breast Cancer
11/20
12/28
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
CLEVER, NCT03032406: Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Active, not recruiting
2
53
US
Hydroxychloroquine, Everolimus
Abramson Cancer Center at Penn Medicine
Breast Cancer Stage IIB
05/22
05/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
PALAVY, NCT04841148: Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

Recruiting
2
96
US
HCQ, Hydroxychloroquine sulfate, Plaquenil, Avelumab, MSB0010718C, Bavencio, Palbociclib, Ibrance
Abramson Cancer Center at Penn Medicine, Johns Hopkins University, Translational Breast Cancer Research Consortium, Pfizer, Breast Cancer Research Foundation
Breast Cancer
07/27
05/28
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT02732171: PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Recruiting
N/A
600
US
Research Blood Collection
Abramson Cancer Center at Penn Medicine
Breast Cancer
04/28
04/30
AURORA US, NCT03737695: Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Suspended
N/A
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Medical Chart Review, Chart Review
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC V8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
09/25
11/27
NCT02530008: Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

Active, not recruiting
N/A
600
US
Abramson Cancer Center at Penn Medicine
Women With Suspected or Confirmed Recurrent Breast Cancer
10/24
10/26
NCT06551116: QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Recruiting
N/A
200
US
CE-10-IVD
Angela DeMichele, Translational Breast Cancer Research Consortium, Danaher Inc.
HER2-positive Metastatic Breast Cancer
09/29
09/29
NCT02798341: The Breast Program - Translational Cancer Resource

Active, not recruiting
N/A
4000
US
Biospecimen Collection
Abramson Cancer Center at Penn Medicine
Breast Cancer
07/28
07/30
Schuster, Stephen J
UPCC 02408, NCT00783367: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Checkmark P2 data in B-cell and MCL
Nov 2011 - Nov 2011: P2 data in B-cell and MCL
Completed
2
50
US
Lenalidomide, Revlimid (lenalidomide), Dexamethasone, Decadron (dexamethasone), Rituximab, Rituxan (rituximab)
Abramson Cancer Center at Penn Medicine
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
11/12
11/20
NCT04305444: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Terminated
2
55
US
DTRM-555, DTRMWXHS-12, everolimus, pomalidomide
Zhejiang DTRM Biopharma
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
12/24
12/24
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
06/26
06/27
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT04419909: Retreatment With CTL019/CTL119

Not yet recruiting
1
12
US
CD19 redirected autologous T cells (CTL019 or CTL119 cells)
University of Pennsylvania
Lymphoma, B-Cell
07/27
07/27
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Ky, Bonnie
NTproBNP-Guide, NCT04737265: Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

Active, not recruiting
1/2
101
US
Biomarker Guided Intervention
Abramson Cancer Center at Penn Medicine, National Heart, Lung, and Blood Institute (NHLBI)
Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma, Cardiomyopathies, Heart Failure
05/25
05/25
CCTGuide Pilot, NCT04023110: Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin And/or Trastuzumab

Completed
1
69
US
Carvedilol, Coreg
Abramson Cancer Center at Penn Medicine
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
08/24
01/25
NCT04467021: Cancer and Blood Pressure Management, CARISMA Study

Active, not recruiting
N/A
61
US
Best Practice, standard of care, standard therapy, Blood Pressure Measurement, Clinical Management, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
09/25
09/25
RADCOMP, NCT02603341: Pragmatic Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer: a Radiotherapy Comparative Effectiveness () Consortium Trial

Active, not recruiting
N/A
1238
US
Photon, Proton
Abramson Cancer Center at Penn Medicine, Patient-Centered Outcomes Research Institute
Breast Cancer
08/28
11/36
NCT04361240: Cardiotoxicity in Breast Cancer Patients Treated with Proton or Photon Radiotherapy: a RadComp Companion Study

Active, not recruiting
N/A
175
US
Proton vs Photon Radiation
Abramson Cancer Center at Penn Medicine, National Heart, Lung, and Blood Institute (NHLBI)
Breast Cancer, Cardiotoxicity
04/25
04/25
CLARITY, NCT04305613: Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy

Enrolling by invitation
N/A
221
US
Chemoradiation
Abramson Cancer Center at Penn Medicine
Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
12/25
12/28
PCT, NCT05096338: Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer

Active, not recruiting
N/A
200
US
Social Determinants of Health
Abramson Cancer Center at Penn Medicine, American Heart Association
Prostate Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
11/29
11/29
NCT01173341: Cardiotoxicity of Cancer Therapy (CCT)

Enrolling by invitation
N/A
700
US
Echocardiography, Blood Collection, Symptoms Questionnaire
Abramson Cancer Center at Penn Medicine
Breast Cancer
04/37
04/37
CCT2, NCT05078190: Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer

Active, not recruiting
N/A
200
US
Social Determinants of Health
Abramson Cancer Center at Penn Medicine, American Heart Association
Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
10/39
10/39
Santa-Maria, Cesar
S2206, NCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Recruiting
3
3680
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Genetic Testing, Genetic Analysis, Genetic Examination, Genetic Test, Mammography, MG, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Localized Breast Carcinoma
05/26
05/26
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT03213041: Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Recruiting
2
100
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
06/22
07/23
NCT04443348: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Recruiting
2
120
US
Radiation Therapy Boost, Pembrolizumab, Keytruda®., Paclitaxel, Taxol, Carboplatin, Paraplatin, Cyclophosphamide, Cytophosphane, Doxorubicin, Adriamycin, Capecitabine
Laura M. Spring, MD, Merck Sharp & Dohme LLC, Breast Cancer Research Foundation, Translational Breast Cancer Research Consortium
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
06/24
12/24
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
TBCRC 048, NCT03344965: Olaparib in Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/25
12/25
ImmunoADAPT, NCT03573648: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Active, not recruiting
2
33
US
Avelumab, Bavencio, Endocrine therapy, Hormone therapy, Palbociclib, Ibrance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Pfizer, Allegheny Health Network, National Institutes of Health (NIH)
Breast Cancer
09/25
12/25
NCT05455658: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Recruiting
2
33
US
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine, STEMVAC, STEMVAC Th1 Polyepitope Plasmid-based Vaccine, Sargramostim, 123774-72-1, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
University of Washington, National Cancer Institute (NCI), University of Wisconsin, Madison
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
04/25
12/25
NeoADAPT, NCT06245889: PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Recruiting
2
30
US
Paclitaxel, Taxol, Carboplatin, Paraplatin, Pembrolizumab, Keytruda, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Olaparib, Lynparza, Capecitabine, Xeloda
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Breast Cancer Research Foundation
Triple Negative Breast Cancer
06/29
06/30
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TBCRC 056, NCT04584255: Niraparib + Dostarlimab in BRCA Mutated Breast Cancer

Recruiting
2
62
US
Niraparib, Zejula, Dostarlimab, TSR042
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Johns Hopkins University, GlaxoSmithKline
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
07/25
07/29
NCT03043794: Study of Stereotactic Radiotherapy for Breast Cancer

Terminated
2
4
US
Stereotactic Body Radiation Therapy SBRT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Robert L. Sloan Fund for Cancer Research
Breast Cancer
10/21
10/23
NCI-2018-01581, NCT03606967: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
2
70
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Personalized Synthetic Long Peptide Vaccine, Personalized SLP Vaccine, TSMA-based SLP Vaccine, TSMA-based Synthetic Long Peptide Vaccine, Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
11/25
11/25
DIRECT, NCT05710328: Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The Trial

Recruiting
2
235
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
ECOG-ACRIN Cancer Research Group
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
05/27
12/29
STU-2021-0657, NCT05029999: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting
1
30
US
PLD Chemotherapy, Pegylated liposomal doxorubicin, CDX-1140, CD40 monoclonal antibody, CDX-301, Flt3 Ligand
University of Texas Southwestern Medical Center, Celldex Therapeutics, Gateway for Cancer Research
HER2-negative Breast Cancer, Metastatic Breast Cancer
04/25
04/25
PRISMM, NCT04447651: Patient Response to Immunotherapy Using Spliceosome Mutational Markers

Active, not recruiting
N/A
6
US
Recommendation for treatment with immunotherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Vanderbilt University, Bristol-Myers Squibb, Avon Breast Health Access Fund
Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation
08/25
08/25
BioLept, NCT06638294: Study in Patients With Breast Cancer Leptomeningeal Metastasis

Recruiting
N/A
30
US
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Avon Foundation
Leptomeningeal Metastasis of Breast Cancer
12/26
12/28
Budzik, Krista
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
NCT03646617: Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Recruiting
2
54
US
Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine, National Cancer Institute (NCI)
Metastatic Melanoma
06/25
12/26
NCT04013854: Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Active, not recruiting
2
67
US
nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine
Melanoma Stage III, Melanoma
08/26
08/26
Mitchell, Tara
NCT03646617: Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Recruiting
2
54
US
Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine, National Cancer Institute (NCI)
Metastatic Melanoma
06/25
12/26
NCT04013854: Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Active, not recruiting
2
67
US
nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine
Melanoma Stage III, Melanoma
08/26
08/26
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
04/25
04/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DeMichele, Angela
PALLAS, NCT02513394 / 2014-005181-30: PALbociclib CoLlaborative Adjuvant Study

Checkmark Presentation of data from PALLAS trial for ER+/HER2- breast cancer at ASCO 2022
Oct 2022 - Oct 2022: Presentation of data from PALLAS trial for ER+/HER2- breast cancer at ASCO 2022
Hourglass Jan 2021 - Jun 2021 : For early-stage breast cancer (PALLAS study)
Checkmark From PALLAS trial for HR+/HER2- breast cancer at ESMO 2020
Sep 2020 - Sep 2020: From PALLAS trial for HR+/HER2- breast cancer at ESMO 2020
More
Active, not recruiting
3
5796
Europe, Canada, Japan, US, RoW
Palbociclib, Standard Adjuvant Endocrine Therapy
Alliance Foundation Trials, LLC., Austrian Breast & Colorectal Cancer Study Group, NSABP Foundation Inc, PrECOG, LLC., Breast International Group, Pfizer
Breast Cancer
11/20
12/28
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
CLEVER, NCT03032406: Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Active, not recruiting
2
53
US
Hydroxychloroquine, Everolimus
Abramson Cancer Center at Penn Medicine
Breast Cancer Stage IIB
05/22
05/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
PALAVY, NCT04841148: Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

Recruiting
2
96
US
HCQ, Hydroxychloroquine sulfate, Plaquenil, Avelumab, MSB0010718C, Bavencio, Palbociclib, Ibrance
Abramson Cancer Center at Penn Medicine, Johns Hopkins University, Translational Breast Cancer Research Consortium, Pfizer, Breast Cancer Research Foundation
Breast Cancer
07/27
05/28
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT02732171: PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Recruiting
N/A
600
US
Research Blood Collection
Abramson Cancer Center at Penn Medicine
Breast Cancer
04/28
04/30
AURORA US, NCT03737695: Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Suspended
N/A
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Medical Chart Review, Chart Review
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC V8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
09/25
11/27
NCT02530008: Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

Active, not recruiting
N/A
600
US
Abramson Cancer Center at Penn Medicine
Women With Suspected or Confirmed Recurrent Breast Cancer
10/24
10/26
NCT06551116: QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Recruiting
N/A
200
US
CE-10-IVD
Angela DeMichele, Translational Breast Cancer Research Consortium, Danaher Inc.
HER2-positive Metastatic Breast Cancer
09/29
09/29
NCT02798341: The Breast Program - Translational Cancer Resource

Active, not recruiting
N/A
4000
US
Biospecimen Collection
Abramson Cancer Center at Penn Medicine
Breast Cancer
07/28
07/30
Schuster, Stephen J
UPCC 02408, NCT00783367: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Checkmark P2 data in B-cell and MCL
Nov 2011 - Nov 2011: P2 data in B-cell and MCL
Completed
2
50
US
Lenalidomide, Revlimid (lenalidomide), Dexamethasone, Decadron (dexamethasone), Rituximab, Rituxan (rituximab)
Abramson Cancer Center at Penn Medicine
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
11/12
11/20
NCT04305444: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Terminated
2
55
US
DTRM-555, DTRMWXHS-12, everolimus, pomalidomide
Zhejiang DTRM Biopharma
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
12/24
12/24
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
06/26
06/27
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT04419909: Retreatment With CTL019/CTL119

Not yet recruiting
1
12
US
CD19 redirected autologous T cells (CTL019 or CTL119 cells)
University of Pennsylvania
Lymphoma, B-Cell
07/27
07/27
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Ky, Bonnie
NTproBNP-Guide, NCT04737265: Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

Active, not recruiting
1/2
101
US
Biomarker Guided Intervention
Abramson Cancer Center at Penn Medicine, National Heart, Lung, and Blood Institute (NHLBI)
Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma, Cardiomyopathies, Heart Failure
05/25
05/25
CCTGuide Pilot, NCT04023110: Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin And/or Trastuzumab

Completed
1
69
US
Carvedilol, Coreg
Abramson Cancer Center at Penn Medicine
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
08/24
01/25
NCT04467021: Cancer and Blood Pressure Management, CARISMA Study

Active, not recruiting
N/A
61
US
Best Practice, standard of care, standard therapy, Blood Pressure Measurement, Clinical Management, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
09/25
09/25
RADCOMP, NCT02603341: Pragmatic Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer: a Radiotherapy Comparative Effectiveness () Consortium Trial

Active, not recruiting
N/A
1238
US
Photon, Proton
Abramson Cancer Center at Penn Medicine, Patient-Centered Outcomes Research Institute
Breast Cancer
08/28
11/36
NCT04361240: Cardiotoxicity in Breast Cancer Patients Treated with Proton or Photon Radiotherapy: a RadComp Companion Study

Active, not recruiting
N/A
175
US
Proton vs Photon Radiation
Abramson Cancer Center at Penn Medicine, National Heart, Lung, and Blood Institute (NHLBI)
Breast Cancer, Cardiotoxicity
04/25
04/25
CLARITY, NCT04305613: Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy

Enrolling by invitation
N/A
221
US
Chemoradiation
Abramson Cancer Center at Penn Medicine
Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
12/25
12/28
PCT, NCT05096338: Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer

Active, not recruiting
N/A
200
US
Social Determinants of Health
Abramson Cancer Center at Penn Medicine, American Heart Association
Prostate Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
11/29
11/29
NCT01173341: Cardiotoxicity of Cancer Therapy (CCT)

Enrolling by invitation
N/A
700
US
Echocardiography, Blood Collection, Symptoms Questionnaire
Abramson Cancer Center at Penn Medicine
Breast Cancer
04/37
04/37
CCT2, NCT05078190: Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer

Active, not recruiting
N/A
200
US
Social Determinants of Health
Abramson Cancer Center at Penn Medicine, American Heart Association
Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
10/39
10/39
Santa-Maria, Cesar
S2206, NCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Recruiting
3
3680
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Genetic Testing, Genetic Analysis, Genetic Examination, Genetic Test, Mammography, MG, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Localized Breast Carcinoma
05/26
05/26
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT03213041: Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Recruiting
2
100
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
06/22
07/23
NCT04443348: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Recruiting
2
120
US
Radiation Therapy Boost, Pembrolizumab, Keytruda®., Paclitaxel, Taxol, Carboplatin, Paraplatin, Cyclophosphamide, Cytophosphane, Doxorubicin, Adriamycin, Capecitabine
Laura M. Spring, MD, Merck Sharp & Dohme LLC, Breast Cancer Research Foundation, Translational Breast Cancer Research Consortium
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
06/24
12/24
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
TBCRC 048, NCT03344965: Olaparib in Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/25
12/25
ImmunoADAPT, NCT03573648: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Active, not recruiting
2
33
US
Avelumab, Bavencio, Endocrine therapy, Hormone therapy, Palbociclib, Ibrance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Pfizer, Allegheny Health Network, National Institutes of Health (NIH)
Breast Cancer
09/25
12/25
NCT05455658: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Recruiting
2
33
US
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine, STEMVAC, STEMVAC Th1 Polyepitope Plasmid-based Vaccine, Sargramostim, 123774-72-1, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
University of Washington, National Cancer Institute (NCI), University of Wisconsin, Madison
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
04/25
12/25
NeoADAPT, NCT06245889: PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Recruiting
2
30
US
Paclitaxel, Taxol, Carboplatin, Paraplatin, Pembrolizumab, Keytruda, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Olaparib, Lynparza, Capecitabine, Xeloda
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Breast Cancer Research Foundation
Triple Negative Breast Cancer
06/29
06/30
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TBCRC 056, NCT04584255: Niraparib + Dostarlimab in BRCA Mutated Breast Cancer

Recruiting
2
62
US
Niraparib, Zejula, Dostarlimab, TSR042
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Johns Hopkins University, GlaxoSmithKline
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
07/25
07/29
NCT03043794: Study of Stereotactic Radiotherapy for Breast Cancer

Terminated
2
4
US
Stereotactic Body Radiation Therapy SBRT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Robert L. Sloan Fund for Cancer Research
Breast Cancer
10/21
10/23
NCI-2018-01581, NCT03606967: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
2
70
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Personalized Synthetic Long Peptide Vaccine, Personalized SLP Vaccine, TSMA-based SLP Vaccine, TSMA-based Synthetic Long Peptide Vaccine, Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
11/25
11/25
DIRECT, NCT05710328: Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The Trial

Recruiting
2
235
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
ECOG-ACRIN Cancer Research Group
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
05/27
12/29
STU-2021-0657, NCT05029999: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting
1
30
US
PLD Chemotherapy, Pegylated liposomal doxorubicin, CDX-1140, CD40 monoclonal antibody, CDX-301, Flt3 Ligand
University of Texas Southwestern Medical Center, Celldex Therapeutics, Gateway for Cancer Research
HER2-negative Breast Cancer, Metastatic Breast Cancer
04/25
04/25
PRISMM, NCT04447651: Patient Response to Immunotherapy Using Spliceosome Mutational Markers

Active, not recruiting
N/A
6
US
Recommendation for treatment with immunotherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Vanderbilt University, Bristol-Myers Squibb, Avon Breast Health Access Fund
Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation
08/25
08/25
BioLept, NCT06638294: Study in Patients With Breast Cancer Leptomeningeal Metastasis

Recruiting
N/A
30
US
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Avon Foundation
Leptomeningeal Metastasis of Breast Cancer
12/26
12/28
Budzik, Krista
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
NCT03646617: Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Recruiting
2
54
US
Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine, National Cancer Institute (NCI)
Metastatic Melanoma
06/25
12/26
NCT04013854: Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Active, not recruiting
2
67
US
nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine
Melanoma Stage III, Melanoma
08/26
08/26
Mitchell, Tara
NCT03646617: Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Recruiting
2
54
US
Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine, National Cancer Institute (NCI)
Metastatic Melanoma
06/25
12/26
NCT04013854: Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Active, not recruiting
2
67
US
nivolumab, Ipilimumab
Abramson Cancer Center at Penn Medicine
Melanoma Stage III, Melanoma
08/26
08/26
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
04/25
04/25

Download Options